Suppr超能文献

在初发糖尿病性黄斑水肿患者中使用扫频源光学相干断层扫描(OCT)和光学相干断层扫描血管造影(OCT-A)对生物标志物进行前瞻性二分法研究。

Prospective and dichotomous study of biomarkers with swept-source OCT and OCT-angiography in naive patients with diabetic macular edema.

作者信息

Rezende Marcussi Palata, Faria Fernanda Atoui, Beraldo Daniel Prado, Polido Julia, Belfort Rubens, Cabral Thiago

机构信息

Department of Ophthalmology, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.

Clinica Oftalmo-Retina, Presidente Prudente, SP, Brazil.

出版信息

Int J Retina Vitreous. 2025 Apr 22;11(1):51. doi: 10.1186/s40942-025-00672-7.

Abstract

BACKGROUND

We used state-of-the-art high-resolution retinal imaging to explore the treatment (loading dose of aflibercept) of diabetic macular edema (DME) among treatment-naive patients. Swept-source (SS) OCT and OCT-Angiography (SS-OCTA) were performed, and a dichotomous analysis was conducted to compare responders and treatment-resistant patients (responsive and resistant). Furthermore, treatment responses were evaluated based on the subdivision of choroidal thickness.

MATERIALS AND METHODS

This prospective, noncomparative, interventional case series study examined the following biomarkers: best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), avascular area of the superficial plexus (AASP), avascular area of the deep plexus (AADP), and vessel density (VD). Data from the baseline and 4-month examinations were compared.

RESULTS

Twenty-eight eyes from 25 patients were included. Significant improvements were observed in BCVA (0.7250 ± 0.23 to 0.3957 ± 0.21; p < 0.000), CMT µm (339.04 ± 66.19 to 265.21 ± 55.75; p < 0.000), CCT µm (221.71 ± 69.69 to 209.07 ± 70.92; p < 0.000), VD (17.90 ± 7.82 to 15.35 ± 5.80; p < 0.038), AASP µm (235,374 ± 91,299 to 157,326 ± 77,815; p < 0.000) and AADP µm (996,335 ± 1,000,047 to 362,161 ± 277,225; p < 0.000). Dichotomous analysis revealed that 15 patients were responsive (53.57%), and 13 resistant (46.43%). There were no significant differences between any of the pretreatment biomarkers. In the subdivision of choroidal thickness, which ranged from 211 to 270 µm (group 3), we found greater reductions in the CCT, AADP and CD. The choroidal thickness ranged from 181 to 210 µm (group 2): BCVA and AASP exhibited the greatest reductions.

CONCLUSION

BCVA, CMT, CCT, AASP, AADP and VD were improved after treatment. The pretreatment biomarkers did not predict treatment response between the responsive and resistant. Regarding choroidal stratification, values within the normal range of CCT showed the greatest reductions, indicating that these values may be more responsive to treatment. Notably, this is the first study to analyze biomarkers provided by SS OCT and OCTA, stratify the choroid, and perform a dichotomous analysis.

摘要

背景

我们使用了最先进的高分辨率视网膜成像技术,来探索初治糖尿病性黄斑水肿(DME)患者的治疗方法(阿柏西普负荷剂量)。进行了扫频源(SS)光学相干断层扫描(OCT)和OCT血管造影(SS-OCTA),并进行了二分法分析,以比较反应者和治疗抵抗患者(反应性和抵抗性)。此外,根据脉络膜厚度细分评估治疗反应。

材料与方法

这项前瞻性、非对比性、介入性病例系列研究检测了以下生物标志物:最佳矫正视力(BCVA)、中心黄斑厚度(CMT)、中心脉络膜厚度(CCT)、浅表丛无血管区(AASP)、深部丛无血管区(AADP)和血管密度(VD)。比较了基线检查和4个月检查的数据。

结果

纳入了25例患者的28只眼。观察到BCVA(从0.7250±0.23提高到0.3957±0.21;p<0.000)、CMT(μm,从339.04±66.19降至265.21±55.75;p<0.000)、CCT(μm,从221.71±69.69降至209.07±70.92;p<0.000)、VD(从17.90±7.82降至15.35±5.80;p<0.038)、AASP(μm,从235374±91299降至157326±77815;p<0.000)和AADP(μm,从996335±1000047降至362161±277225;p<0.000)有显著改善。二分法分析显示,15例患者有反应(53.57%),13例抵抗(46.43%)。任何治疗前生物标志物之间均无显著差异。在脉络膜厚度细分中,范围为211至270μm(第3组),我们发现CCT、AADP和CD的降低幅度更大。脉络膜厚度范围为181至210μm(第2组):BCVA和AASP的降低幅度最大。

结论

治疗后BCVA、CMT、CCT、AASP、AADP和VD均有改善。治疗前生物标志物无法预测反应者和抵抗者之间的治疗反应。关于脉络膜分层,CCT正常范围内的值降低幅度最大,表明这些值可能对治疗更敏感。值得注意的是,这是第一项分析SS OCT和OCTA提供的生物标志物、对脉络膜进行分层并进行二分法分析的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec78/12016437/dec011bbc8fd/40942_2025_672_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验